Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Henan Cancer Hospital is the lead sponsor of 76 current clinical trials in our China register. 50 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Carboplatin, Trastuzumab and Trastuzumab Rezetecan. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting5066%
Not yet open2026%
Active, closed57%
By invitation11%

Trials by phase

Phase 24053%
Observational1520%
Phase 379%
Not applicable57%
Phase 1/257%
Phase 134%
Phase 411%

Clinical trials sponsored by Henan Cancer Hospital

76 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer NCT05063136 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Capecitabine	Phase 3	Recruiting	2021-09	China
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases NCT07100600 · ClinicalTrials.gov ↗ · HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy Drug: Trastuzumab Rezetecan	Phase 2	Recruiting	2025-08	China
NabPE With or Without Serplulimab for Early-stage HR+/HER2- Breast Cancer. NCT06781281 · ClinicalTrials.gov ↗ · Breast Cancer Invasive Drugs: NabPE, Serplulimab	Observational	Recruiting	2024-12	China
RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors NCT06546150 · ClinicalTrials.gov ↗ · KRAS G12D, T Cell Therapy	Phase 1	Recruiting	2024-03	China
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer NCT06860529 · ClinicalTrials.gov ↗ · HR+/HER2- Breast Cancer Drugs: Albumin paclitaxel, Epirubicin, Serplulimab	Phase 2	Recruiting	2025-04	China
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis NCT06643000 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation Drug: Furmonertinib	Not applicable	Recruiting	2024-12	China
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC NCT07244016 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Observational	Recruiting	2025-02	China
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma NCT05495152 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drug: Sintilimab	Phase 3	Recruiting	2022-08	China
Correlation Between Driver Gene Abnormalities and Clinicopathological Characteristics and Disease Prognosis in Lymphoma NCT04263935 · ClinicalTrials.gov ↗ · Lymphoma, Gene Abnormality	Observational	Recruiting	2019-01	China
Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors NCT05468970 · ClinicalTrials.gov ↗ · Bone and Soft Tissue Tumors, Clinical Features	Observational	Recruiting	2022-08	China
Evaluating Safety ,Tolerability, Pharmacokinetic,Efficacy of WJ01024 or WJ01024 Combined With Ruxolitinib in Patients With Myelofibrosis NCT07802405 · ClinicalTrials.gov ↗ · MF With Splenomegaly	Phase 1	Recruiting	2023-11	China
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC NCT06927180 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3) Drugs: Albumin paclitaxel, Carboplatin, Docetaxel	Phase 2	Recruiting	2025-04	China
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases NCT05769010 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer Drugs: Adebelizumab, Bevacizumab, Pyrotinib	Phase 2	Recruiting	2023-03	China
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 NCT07264569 · ClinicalTrials.gov ↗ · Meningeal Metastasis Drug: BioTTT001	Phase 1/2	Recruiting	2025-06	China
Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma NCT05209620 · ClinicalTrials.gov ↗ · Central Nervous System Lymphoma	Phase 2	Recruiting	2021-12	China
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial NCT06176534 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Treatment, HR Low/HER2 Negative	Phase 2	Recruiting	2024-01	China
Evaluation of the Effectiveness and Safety of Laparoscopic Assisted Mastectomy With Preservation of Nipple and Areola, Immediate One-step Breast Reconstruction With Pectoral Muscle Prosthesis and Patch, and Simultaneous Autologous Fat Transplantation NCT07037537 · ClinicalTrials.gov ↗ · Breast Cancer Patients	Not applicable	Recruiting	2024-10	China
Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer NCT06518135 · ClinicalTrials.gov ↗ · Sentinel Lymph Node Biopsy	Observational	Recruiting	2024-04	China
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis NCT06945705 · ClinicalTrials.gov ↗ · NSCLC Drugs: Anlotinib, Furmonertinib	Phase 2	Recruiting	2025-04	China
Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma NCT07233720 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma Drugs: Rituximab, Zanubrutinib	Observational	Recruiting	2025-11	China
Lenvatinib for Advanced Bone and Soft Tissue Sarcoma NCT05617859 · ClinicalTrials.gov ↗ · Effectiveness, Sexuality Drug: Lenvatinib	Phase 2	Recruiting	2023-04	China
Exploration of the Application of Methotrexate-loaded Drug Vesicles in Intrathecal Injection for Meningeal Metastasis of Lung Cancer NCT07559097 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis From Lung Cancer	Phase 1/2	Recruiting	2025-09	China
Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC NCT05918328 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer Drugs: Albumin paclitaxel, Carboplatin, Docetaxel	Phase 2	Recruiting	2023-05	China
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC NCT06817525 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	2024-11	China
Organoid-guided Personalized Treatment of Pleural Effusion NCT06959173 · ClinicalTrials.gov ↗ · Lung Cancer	Observational	Recruiting	2025-02	China
TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer NCT06293014 · ClinicalTrials.gov ↗ · Colorectal Cancer Drugs: Bevacizumab, Trifluridine/Tipiracil	Phase 2	Recruiting	2024-02	China
A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG NCT06774222 · ClinicalTrials.gov ↗ · Gastric/Gastroesophageal Junction Adenocarcinoma Drug: Fruquintinib	Phase 2	Recruiting	2023-09	China
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT07057427 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Nab-paclitaxel, Pertuzumab, Trastuzumab	Phase 3	Recruiting	2025-06	China
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer NCT06967103 · ClinicalTrials.gov ↗ · Breast Cancer, HR+/HER2- Breast Cancer Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-09	China
Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy NCT07629817 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Nab-paclitaxel, Toripalimab	Phase 3	Recruiting	2026-06	China
A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early Breast Cancer NCT04547907 · ClinicalTrials.gov ↗ · Breast Cancer,HER2-positive Drugs: Carboplatin, Docetaxel, Nab-paclitaxel	Phase 3	Recruiting	2020-09	China
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer NCT05377658 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drugs: Albumin-Bound Paclitaxel, Cadonilimab, Carboplatin	Phase 2	Recruiting	2022-07	China
Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer NCT07334431 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastric (Stomach) Cancer, GEJ Adenocarcinoma Drug: Xelox	Phase 1/2	Recruiting	2024-02	China
A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer NCT07540533 · ClinicalTrials.gov ↗ · Advanced Breast Cancer Drug: Toripalimab	Phase 2	Recruiting	2026-01	China
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer NCT05398861 · ClinicalTrials.gov ↗ · HER-2 Negative Breast Cancer Drugs: Bevacizumab, Utidelone	Phase 2	Recruiting	2022-08	China
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN NCT07187908 · ClinicalTrials.gov ↗ · Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia Drug: Efbemalenograstim alfa	Phase 2	Recruiting	2025-01	China
Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer NCT06329973 · ClinicalTrials.gov ↗ · Metastatic Gastroesophageal Junction Adenocarcinoma Drug: Fruquintinib	Phase 1/2	Recruiting	2024-02	China
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer NCT06276868 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer Drug: Letrozole	Phase 2	Recruiting	2024-01	China
A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy NCT07559786 · ClinicalTrials.gov ↗ · SCLC, Limited Stage	Phase 2	Recruiting	2026-07	China
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903) NCT04138212 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drug: Paclitaxel, Cisplatin	Phase 3	Recruiting	2019-10	China
Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors NCT05596344 · ClinicalTrials.gov ↗ · Malignant Tumor, Anxiety, Depression	Observational	Recruiting	2023-05	China
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib NCT06478927 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drug: Palbociclib	Not applicable	Recruiting	2024-01	China
Toripalimab Plus FLOT in Locally Advanced Gastric Cancer NCT04891016 · ClinicalTrials.gov ↗ · Chemotherapy, Immune Checkpoint Inhibitor, Locally Advanced Gastric Carcinoma Drugs: FLOT, Toripalimab	Phase 2	Recruiting	2021-06	China
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma NCT04280822 · ClinicalTrials.gov ↗ · Esophageal Cancer, Surgery, Neoadjuvant Treatment	Phase 3	Recruiting	2020-04	China
Efficacy and Safety of Prepectoral Prosthesis Immediate One-Stage Breast Reconstruction Versus Two-Stage Expander/Prosthesis Reconstruction in Postoperative Adjuvant Radiotherapy Breast Cancer Patients: A Prospective, Single-Center, Cohort Study NCT07037576 · ClinicalTrials.gov ↗ · Breast Cancer Patients	Observational	Recruiting	2025-05	China
To Evaluate the Efficacy and Safety of Ipsilateral Supraclavicular Lymph Node Dissection for Breast Cancer Patients NCT06605521 · ClinicalTrials.gov ↗ · Locally Advanced Breast Cancer	Observational	Recruiting	2023-04	China
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer NCT05911958 · ClinicalTrials.gov ↗ · HER2 Low Breast Carcinoma Drug: Trastuzumab Rezetecan	Phase 2	Recruiting	2023-07	China
The Maintenance Treatment of "ITIVA" in AML Patients NCT06256627 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Maintenance Treatment, Minor Residue Disease	Not applicable	Recruiting	2023-07	China
Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma NCT06749730 · ClinicalTrials.gov ↗ · Unresectable Biliary Tract Carcinoma Drugs: Adebrelimab, Apatinib, Gemcitabine and cisplatin	Phase 2	Recruiting	2024-04	China
Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma NCT04737889 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma Drugs: Lenalidomide, Methotrexate, Rituximab	Phase 2	Recruiting	2021-01	China
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC NCT06465238 · ClinicalTrials.gov ↗ · NSCLC Drugs: SHR-A1921, SHR-A2009	Phase 2	Not yet open	2024-06	China
Application of LARS Ligament in Bone Prosthesis Replacement NCT05616182 · ClinicalTrials.gov ↗ · Malignant Tumor	Observational	Not yet open	2024-12	China
Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure NCT07817654 · ClinicalTrials.gov ↗ · GC, GEJC Drugs: Retlirafusp alfa, Trastuzumab Rezetecan	Phase 2	Not yet open	2026-09	China
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer NCT06934733 · ClinicalTrials.gov ↗ · Advanced or Metastatic Breast Cancer	Not applicable	Not yet open	2025-05	China
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma NCT07459608 · ClinicalTrials.gov ↗ · Indolent Lymphoma, WM, MZL Drug: Lisaftoclax	Phase 2	Not yet open	2026-07	China
Application of 3D Printed Prosthesis in Limb Salvage Surgery for Bone Tumors NCT05616195 · ClinicalTrials.gov ↗ · Malignant Tumor	Observational	Not yet open	2024-12	China
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma NCT07472621 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma	Observational	Not yet open	2026-03	China
Application of Antiosteoporosis Therapy in Osteolysis NCT05617846 · ClinicalTrials.gov ↗ · Limb; Fusion, Complication	Observational	Not yet open	2024-12	China
Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer NCT07610629 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma Drugs: Apatinib, Nab-paclitaxel, Retlirafusp alfa	Phase 2	Not yet open	2026-05	China
SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer NCT07125950 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Not yet open	2025-09	China
RE001 T Cell Injection for the Treatment of KRAS G12V Mutated Solid Tumors NCT06545201 · ClinicalTrials.gov ↗ · KRAS G12V, T Cell Therapy	Phase 1	Not yet open	2024-08	China
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study NCT06685354 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 2	Not yet open	2024-11	China
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure NCT06786208 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Drug: Sunvozertinib	Observational	Not yet open	2025-02	China
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain NCT06897917 · ClinicalTrials.gov ↗ · Opioid-Induced Constipation, Pain Cancer	Phase 4	Not yet open	2025-04	China
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer NCT06554028 · ClinicalTrials.gov ↗ · Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Neoplasms Drug: Tislelizumab	Phase 2	Not yet open	2024-08	China
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia NCT06793228 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage Drugs: Nanocrystalline Megestrol Acetate, Tislelizumab	Phase 2	Not yet open	2025-01	China
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer. NCT07136974 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 + Breast Cancer Drugs: Carboplatin, Docetaxel, Pertuzumab	Phase 2	Not yet open	2025-09	China
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06236997 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma Drug: Adebrelimab	Phase 2	Not yet open	2024-02	China
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy NCT07684950 · ClinicalTrials.gov ↗ · Mantle Cell Lymphoma (MCL) Drugs: Lisaftoclax, Pirtobrutinib	Phase 2	Not yet open	2026-06	China
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors NCT06955390 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1/2	Not yet open	2025-05	China
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib NCT06370416 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Trilaciclib	Phase 2	By invitation	2024-04	China
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma NCT03950271 · ClinicalTrials.gov ↗ · Gastric Cancer Drug: Camrelizumab	Phase 2	Active, closed	2020-01	China
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer NCT05177068 · ClinicalTrials.gov ↗ · Gastric Cancer Drugs: Fruquintinib, Sintilimab	Phase 2	Active, closed	2022-05	China
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma NCT04067037 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma Drugs: Camrelizumab, Dacarbazine, Epirubicin	Phase 2	Active, closed	2019-08	China
Serplulimab Plus Chemotherapy for Early-stage HR+/HER2- Breast Cancer NCT06394661 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: NabPE, Serplulimab	Phase 2	Active, closed	2024-04	China
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma NCT06888531 · ClinicalTrials.gov ↗ · Esophageal Malignant Neoplasm Primary	Phase 2	Active, closed	2025-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Henan Cancer Hospital trials

53 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 13 more in the trial list above.

Conditions in Henan Cancer Hospital trials

93 conditions

Breast Cancer7 Malignant Tumor3 Non-small Cell Lung Cancer3 Esophageal Squamous Cell Carcinoma3 Advanced Breast Cancer3 Gastric Cancer2T Cell Therapy2NSCLC2 HR+/HER2- Breast Cancer2 Gastric Adenocarcinoma2Breast Cancer Patients2HER2-positive Breast Cancer2HER2-positive Advanced Breast Cancer1Brain Metastases1 Radiotherapy1 Breast Cancer Invasive1KRAS G12D1GC1GEJC1Advanced or Metastatic Breast Cancer1Leptomeningeal Metastasis1EGFR Gene Mutation1Extensive-stage Small-cell Lung Cancer1 Lymphoma1

By trial register

Register	Trials	Recruiting
Clinical trials in China	76	50

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Henan Cancer Hospital trials

How many clinical trials does Henan Cancer Hospital sponsor?

Henan Cancer Hospital is the lead sponsor of 76 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Henan Cancer Hospital trials recruiting?

Yes. 50 of its 76 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Henan Cancer Hospital testing?

Its current trials name 53 drugs and biologicals as interventions. The most frequent are Carboplatin (5), Trastuzumab (5), Trastuzumab Rezetecan (5), Docetaxel (4) and Nab-paclitaxel (4). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Henan Cancer Hospital clinical trials